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supraventricular tachycardias: 
Report of the first experience in Hawaii 
Edward N Shen MD 
Other than atrial fibrillation-flutter, the majority of 
supraventricular tachya"hythmias involve either a macro-re-
entry circuit utilizing an atrioventricular (AV) accessory path-
way or a micro-re-entry circuit inside or around the AV node. 
The traditional form of therapy has been medical, with sup-
pression by antiarrhythmic agents, most of which carry a 
heavy side-effect profile. The established alternative for medi-
cal therapy has been surgery, with open-chest excisional abla-
tion of the accessory pathway or cryo-modification of the AV 
node. Even though, as opposed to medical therapy, surgery 
promises cure, it requires thoracotomy and cardiopulmonary 
bypass with significant associated morbidity and even mortal-
ity, as well as high cost. Ten years ago, the technique of "ful-
guration" was first introduced, which involved the delivery of 
an electrical charge through specialized cathetersl. Our first 
experience with this technique was reported in this Journal'. 
Unfortunately, despite being a much better tolerated curative 
procedure involving a very brief hospitalization, the use of 
high-energy direct current (DC) shocks is associated with a 
low but significant incidence of serious complications includ-
ing cardiac perforation, hypotension, coronary artery spasm, 
and late occurrence of ventricular fibrillation'. Concerns 
about these potential complications have markedly limited the 
application of the catheter technique. In the past 2 years, 
adoption ofradio{requency (RF) current as the energy source 
has allowed the ablation to be performed in a very efficacious 
and much safer fashion6- 9• We would like to report the first 
experience with this technique in Hawaii. 
Case reports 
Case 1 - A 64-year-old retired man with paroxysmal 
rapid palpitations for 12 years had episodes that were typically 
associated with severe weakness, lasting up to 16 hours. He 
had a baseline right bundle branch block and his tachycardia 
was documented as having the same configuration, with a rate 
of 165 per minute. He had failed to respond to empiric drug 
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therapy with digoxin and propranolol. Electrophysiologic (EP) 
study demonstrated classic AV nodal re-entrant tachycardia 
(down slow, up fast). In the study, intravenous procainamide 
resulted in suppression of the induction of tachycardia. He 
responded to the agent clinically but developed lupus syn-
drome, requiring drug discontinuation. 
Therefore, he underwent catheter modification of the AV 
node. RF current was delivered through an enlarged-tip elec-
trode on a quadripolar electrode catheter at 40 volts in discrete 
applications of up to 30 seconds. The "anterior" approach was 
used, which allowed for selective ablation of the fast AV 
nodal pathway (Figure lA). Post ablation, the patient had a 
prolongation of atrial-His (AH) interval (from 90 to 140 mil-
liseconds) and PR interval (from 0.16 to 0.23 seconds) with 
no tachycardia inducible. There was no evidence of myocar-
dial damage by electrocardiogram (EKG), cardiac enzymes 
and echocardiogram. The patient was discharged 2 days post-
procedure and had no tachycardia recurrence on followup. 
Figure 1 A. Electrode catheter positions during electrophysio-
logic (EP) testing and radio-frequency (RF) catheter modifica-
tion in Case 1. HIS = catheter in His position. RA = catheter in 
right atrium. RV = catheter in right ventricle. Note the larger tip 
of the catheter in the His position. 
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Figure 1 B. Electrode catheter positions during EP testing and 
RF catheter ablation in Case 2. CS = catheter in coronary 
sinus. HIS = catheter in His position. RA = catheter in right 
atrium. LV= catheter in left ventricle. 
Case 2 - A 30-year-old housewife had had rapid palpita-
tions since age 22. The average duration of her palpitations 
was 30 minutes. 12-lead EKG demonstrated Wolff-Parkinson-
White (WPW) syndrome with suggestion of a posteroseptal 
AV accessory pathway (negative delta waves VI, III, aVF, 
positive delta waves V2-V6, I and aVL). Baseline EP study 
localized the accessory pathway at the ostium of the coronary 
sinus. The accessory pathway effective refractory period was 
280 milliseconds (shortening to 240 milliseconds post isopro-
terenol). Classic AV reciprocating tachycardia (down AV 
node, up accessory pathway) was inducible, with rate of 200 
per minute. Repeat testing on oral moricizine demonstrated 
complete blockage of the accessory pathway with no tachycar-
dia inducible. However, the patient developed mild neurologi-
cal side effects on the agent. For personal reasons she wanted 
to be drug free. 
She underwent ablation of the accessory pathway. RF ener-
gy was applied at ·60 volts for up to 30 seconds through the 
same catheter as described in the previous case. Initial appli-
cation of the energy in the right atrium above the ostium of the 
coronary sinus was unsuccessful, resulting only in transient 
<:onduction loss through the accessory pathway. 
Subsequently, the left ventricular approach was used. The 
catheter was prolapsed across the aortic valve and the tip was 
placed under the mitral valve leaflet on the mitral annulus, 
close to the posterior edge of the septum (Figure IB). Applica-
tion of RF energy here readily resulted in persistent loss of 
preexcitation. Again, post procedure, there was no evidence of 
myocardial damage by EKG, cardiac enzymes and echocar-
diogram. The patient was discharged 2 days post-procedure. 
There was no tachycardia recurrence on followup. 
Case 3 to 6 (See Table 1)- These cases involved 3 AV 
nodal modifications and one left lateral accessory pathway 
ablation, all successful. 
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Figure 2A. Mechanism of atrioventricular (AV) nodal reentrant 
tachycardia, A = atrium, V = ventricle, FAVN = fast AV nodal 
pathway, SAVN =slow AV nodal pathway. 
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Figure 28. Mechanism of orthodromic AV reciprocating tachy-
cardia. A = atrium, AP = accessory pathway, AVN = AV node, 
V .. ventricle. 
Discussion 
Mechanism 
Cases I and 2 typify the majority of patients with problem-
atic supraventricular tachycardias. In both patients, the tachy-
cardia mechanism is re-entry or circus movement. During AV 
nodal re-entrant tachycardia, the circuit is inside or around the 
AV node. It involves antegrade conduction down a slow path-
way and retrograde conduction up a fast pathway, both 
appearing to be anatomically distinct entities, with the fast 
pathway having a more superior (anterior) location around the 
node (Figure 2A). In orthodromic AV reciprocating tachycar-
dia with WPW syndrome, the circuit entails antegrade con-
duction down the normal AV conduction system, across the 
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intervening ventricular myocardium, retrograde conduction up 
the accessory pathway, and across the intervening atrium (Fig-
ure 2B). The purpose of drugs or ablation therapy (surgical, 
DC current, RF current) is to interrupt the re-entrant circuit 
pharmacologically or physically. 
Technique 
The diagnostic portion of the procedure first requires 
intracardiac placement of 3 quadripolar electrode catheters, 
introduced through right or left femoral vein under local anes-
thesia and positioned in the right ventricular apex, the His 
position (across the tricuspid valve) and high in the right atri-
um. Another quadripolar electrode catheter is inserted into the 
coronary sinus (large vein running in the AV sulcus posterior-
ly on the left), usually introduced via the right internal jugular 
vein. With these catheter positions intracardiac mapping is 
possible, from the right, left and septal atrium; stimulation is 
possible from both atria and the right ventricle. With pro-
grammed electrical stimulation, the tachycardia mechanism is 
defined and the location of any accessory pathway is precisely 
determined if present. 
Once the mechanism has been defined, RF catheter abla-
tion or modification can be performed. RF current is a form of 
electrical energy with frequency range of 150kHz to 1.0 MHz 
(by comparison, audible sound is 20 to 20,000 Hz, ultrasound 
1.0 MHz to IOMHz, microwave 1,000 MHz to 3,000 MHz). In 
a low-power, bipolar mode with a continuous unmodulated 
sinusoid waveform, the energy can be harnassed to cause 
well-demarcated coagulation necrosis of myocardial tissue 
without sparking, gas bubble formation or cellular destruction 
of blood elements (common problems with the fulguration 
form of catheter ablation, which uses a monophasic damped 
sinusoid "direct" current at much higher voltage). For our pur-
poses, the RF current is generated by an electiosurgical unit 
(model RFG-3C, Radionics, Burlington, Mass.) at a frequency 
of 350 kHz and given via a 7 French quadripolar catheter with 
a movable curve (Mansfield-Webster, Watertown, Mass.) The 
current is delivered between the large tip electrode on the 
catheter and an indifferent patch electrode on the patient's 
chest, usually at 40-60 volts. Because of the very high fre-
quency, there is no neuromuscular stimulation and general 
anesthesia is not required. 
For AV nodal re-entrant tachycardia, the key to success is 
modification or elimination of the fast or slow AV nodal path-
way with preservation of overall AV conduction. Develop-
ment of high grade or complete AV block is considered a 
complication. 
There are 2 variations in the technique. In the "anterior" 
approach, the fast AV nodal pathway is ablated. The special-
ized catheter is first positioned across the tricuspid valve 
where a good His potential can be obtained. The catheter is 
then progressively pulled back until an atrial ventricular elec-
trogram ratio of more than 1.0 is reached, and the His poten-
tial is barely recordable (Figure lA). RF energy is then 
applied. 
The endpoint of success is an increase of at least 50% in 
the AH interval, elimination or marked slowing of ventricu-
loatrial conduction and inability to induce tachycardia after-
wards. The prolongation of AH interval (AV nodal conduction 
time) occurs because, with ablation of the fast AV nodal path-
way, antegrade conduction through the node occurrs only 
through the slow pathway. This was the protocol used in 
Cases 1, 4 and 5. 
The slow AV nodal pathway, which has a more inferior 
(posterior) orientation, can be eliminated by using the "poste-
rior" approach. In this technique, RF energy is applied to the 
Table 1 - PATIENT PROFILE 
Tachycardia Rate Drugs Heart RF 
Case Age Sex Mechanism (beats/min) Symptoms Used Disease Outcome Complications 
1 64 M AVN 170 p,w D,P,Pn 0 +,F 0 
2 30 F WPW 200 p M' 0 + 0 
3 58 F AVN 175 c,p D,Pn,V 0 +,S DVT 
4 37 F AVN 250 d,l,p D,P,V 0 +F 0 
5 50 F AVN 230 p,w v 0 +,F 0 
6 24 M WPW 200 l,p,s D,F,Pn CM,M" + 0 
O,V 
F = female M = male 
AVN =atrioventricular (AV) nodal reentrant tachycardia. 
WPW = Wolff-Parkinson-White syndrome with orthodromic AV reciprocating tachycardia. 
c = chest pain, d = dyspnea, 1 = lightheadedness, p = palpitations, s = syncope, w = weakness 
D = dispyramide, M' = moricizine, P = propanolol, Pn = procainamide, Q = quinidine, V = verapamil 
+=successful,-= unsuccessful, F =fast AV nodal pathway eliminated, S =slow AV nodal pathway eliminated 
CM = cardiomyopathy, M" = malposition, DVT = deep vein thrombophlebitis 
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right atrium between the His bundle location and the ostium 
of the coronary sinus. Since the fast pathway is not affected, 
the AH and PR intervals will not be changed. The endpoint of 
success is elimination of the dual AV nodal curves during pro-
grammed extrastimulus stimulation, as well as the inability to 
induce tachycardia. We have used this protocol in Case 3 and 
have found equal success with it. 
For ablation of AV accessory pathways in the WPW syn-
drome, the location of the pathway is first defined by mapping 
of the atrial depolarization sequence during ventricular pacing 
and orthodromic tachycardia. Measurement of accessory path-
way potential as a means of localization is helpful but too time 
consuming. We have found instead the shortest AV interval 
highly useful. For left free-wall pathways, the specialized 
catheter is first introduced through the femoral artery and 
advanced retrogradely through the aortic valve into the left 
ventricle. The large tip electrode is placed beneath the mitral 
leaflet and against the mitral annulus (the annulus is well out-
lined by the catheter in the coronary sinus). RF energy is 
applied at the location previously mapped, where a very short 
AV interval can be measured. 
For right free wall and anteroseptal accessory pathways, 
right internal jugular venous access is generally used. The 
specialized catheter is advanced through the right atrium into 
the right ventricle and then curled up below the tricuspid 
valve with the tip electrode aganist the tricuspid annulus. The 
tricuspid annulus can be outlined by a wire placed in the right 
coronary artery. 
There are 2 approaches to posteroseptal pathways, both 
described previously in Case 2. In our case, the left ventricular 
approach (Figure IB) was successful, probably attesting to a 
very oblique orientation of the accessory pathway. 
The endpoint of success is complete elimination of both 
antegrade and retrograde conduction through the accessory 
pathway with no tachycardia inducible afterwards. In our 
patients, there was complete loss of preexcitation with elimi-
nation of delta waves on the surface EKG, a change in the ret-
rograde AV conduction sequence (with the earliest site of ret-
rograde depolarization being the septal atrium, suggesting 
conduction only through the normal AV conduction system 
and not eccentrically through the accessory pathway), as well 
as non-inducibility of the tachycardia. 
There is currently almost no experience with atrial flutter. 
However, since the majority of flutters involve a macro-re-
entry circuit in the right atrium with a zone of slow conduc-
tion in the low right atrium, this arrhythmia is potentially also 
amenable to RF catheter cure. 
Efficacy and Complications 
The reported success rate in the literature has been 92 to 
98%. In our experience with 6 patients so far, the technique 
has been uniformly successful. 
For AV nodal modification and for ablation of posterosep-
tal AV accessory pathways, there is a reported low incidence 
of high grade AV block (about 1 %). In the 2 largest series 
reported so far· 6, there have been less than 1% incidence of 
pericarditis, cardiac tamponade and myocardial infarction 
(one case each). The case of myocardial infarction reported 
occurred by inadvertent introduction of the catheter into the 
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circumflex artery rather than the aortic valve (a complication 
which can be avoided by an experienced catheterizer). In the 
one case of pericardia! tamponade and the other case of peri-
carditis, the RF current was applied in a small branch of the 
coronary sinus. It appears that avoidance of delivery of RF 
energy inside the coronary sinus or its branches may eliminate 
these complications altogether. 
In our experience, deep vein thrombophlebitis in the right 
leg from catheter insertion occurred in Case 3. This is a com-
plication which may be seen infrequently during routine elec-
trophysiologic studies (generally related to multiple catheter 
insertion into the same vein and prolonged duration of the 
procedure) and is not unique to the RF technique. It has now 
become our practice to give patients 3000 units of heparin 
intravenously at the beginning of the procedure and 1000 units 
every additional hour. 
Theoretically, clinically significant thromboembolic events 
may occur whenever a catheter is placed in the arterial circula-
tion. With accumulation of a larger experience worldwide, a 
low incidence of strokes (so far unreported) may come to light 
as a result of ablation of left-sided accessory pathways which 
requires arterial catheterization. This incidence may be mini-
mized or eliminated by heparinization as well as by intermit-
tent inspection of the ablation catheter tip for coagulum 
(chared). A coagulum is generally suspected when there is a 
rapid rise in measured impedance during the application of RF 
energy. 
A comparison 
Even though similar efficacy is achievable through open-
chest surgical procedures, the 5 to 10% incidence of morbidity 
(bleeding, infection, stroke, atelectasis, sternal dehiscence, 
Dressler's syndrome, etc, not considering chest pain which 
occurs in all) and prolonged recovery time will make surgery 
a much less attractive option. 
Empiric antiarrhythmic therapy (unguided by EP testing) 
is, of course, noninvasive. However, even if an effective agent 
could be found by trial-and-error, the high frequency of side 
effects (20 to 50)% for most drugs) as well as the specter of 
life-threatening proarrhythmia would make this alternative 
also quite undesirable. Furthermore, the majority of the 
patients with supraventricular tachycardias tend to be young 
(for women, in the reproductive age). The prospect of facing 
40 or 50 years of taking medications (up to 3 times a day) is 
unacceptable to many, even back in the dark ages when no 
other treatment was available. 
Finally, what about expenses? The total charge for surgery 
is about $50,000, for RF ablation about $7,500. At first 
glance, the cost of generic verapamil (80 mg 3 times a day) at 
$24.45 a month appears to be a real bargain. But taking it over 
a period of 40 years will need $34,713 (assuming 5% a year 
inflation). Even if the patient has the foresight to stockpile 40 
years' worth with one visit, it will still require $11,736 (and 
storage space for 43,810 pills). Understandably, this does not 
include the cost of the occasional emergency room visit for 
breakthroughs (from noncompliance or otherwise). Further-
more, medical therapy is probably inappropriate for patients 
with WPW syndrome and "fast" accessory pathways, who are 
at risk for sudden death10• 11 • 
HAWAII MEDICAL JOURNAL-VOL. 51, No. 2-FEBRUARY 1992 
Conclusion 
Radio-frequency catheter ablation is a highly successful, 
safe and relatively inexpensive technique which will revolu-
tionalize the treatment of re-entrant supraventricular tachy-
arrhythmias. It is quite probable that in the near future any 
patient with sustained supraventricular tachycardia may be 
admitted to hospital, undergo the diagnostic and RF catheter 
procedure the same day, and be discharged within 1 to 2 days 
without having to go through the rather unpleasant experience 
of diarrhea (quinidine), joint pains (procainamide), dry mouth 
(disopyrarnide), constipation (verapamil), or disturbing phone 
calls from a relative warning about sudden death (flecainide). 
I can recall in my previous article on fulguration the compar-
ison of the relationship between catheter ablation and surgery 
for arrhythmia (known as arrhythmia surgery) to that between 
percutaneous transluminal coronary angioplasty and coronary 
artery bypass surgery. This is actually quite invalid. As every-
one knows, there is no cure for coronary artery disease. 
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